Anteris Technologies Announces Major Equity Offering and Medtronic Deal

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAnteris Technologies Global Corp. ( (AVR) ) has issued an update. On January 20, 2026, Anteris Technologies Global Corp. agreed to an underwritten public offering of 34,782,609 common shares at $5.75 per share and granted underwriters a 30‑day option for an additional 5,217,391 shares, which was fully exercised, with the offering expected to close on January 22, 2026. In parallel, the company entered into a private placement with Covidien Group S.à r.l., a Medtronic subsidiary, for 15,652,173 common shares at the same price, bringing total expected gross proceeds from the offering and private placement to about $320 million to fund the PARADIGM global pivotal trial of its DurAVR transcatheter heart valve, expand manufacturing, support v2vmedtech R&D, and bolster working capital. The transactions embed lock-up agreements for executives and directors, and grant Medtronic’s subsidiary registration and investor rights, including participation rights in future equity issuances, transfer restrictions, standstill and voting commitments, a non-voting board observer seat, and a structured right to negotiate on certain future acquisition proposals, deepening a strategic alignment with a major industry player while influencing Anteris’s future governance and capital-raising flexibility. The most recent analyst rating on (AVR) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page. Spark’s Take on AVR Stock According to Spark, TipRanks’ AI Analyst, AVR is a Neutral. The score is held back primarily by weak financial performance (declining revenue, large losses, and negative cash flow). Technicals and recent corporate events are constructive (price above key averages, positive MACD, and meaningful clinical/regulatory milestones), but valuation remains challenging due to ongoing losses and no dividend support. To see Spark’s full report on AVR stock, click here. More about Anteris Technologies Global Corp. Anteris Technologies Global Corp. operates in the structural heart therapeutics and medical device sector, focusing on transcatheter heart valve technologies. Its primary product development includes the DurAVR Transcatheter Heart Valve for patients with severe aortic stenosis, supported by a global pivotal trial strategy and associated manufacturing and R&D activities, including work through subsidiary v2vmedtech, inc. Average Trading Volume: 525,971 Technical Sentiment Signal: Strong Buy Current Market Cap: $236.9M